BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma
1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the ...
Tag: MRD
Daratumumab linked to improved progression-free survival and MRD-negativity in transplant-eligible myeloma patients
1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction and consolidation therapy led to superior progression-free survival ...